PDCD1 and pneumonitis: Pneumonitis appears perhaps slightly less common for the combination of pembrolizumab and axitinib (3%, with one fatal case) compared with single-agent anti-PD-1/PD-L1, although these have not been directly compared prospectively (Atkins et al., 2021).